Abstract
Background
Ireland had the highest prostate cancer incidence in Europe in 2006. In that year, the National Cancer Forum (NCF) recommended against prostate specific antigen (PSA) testing for population-based screening.
Aims
To investigate (1) PSA services and (2) impact of the NCF recommendation.
Methods
Questionnaires were dispatched to biochemistry laboratories nationwide in 2006 and 2007.
Results
All 55 laboratories responded in 2006; 33/36 (89%) responded in 2007. 36 laboratories measured total PSA (tPSA); 14 measured free PSA (fPSA). Laboratories with higher tPSA workload were more likely to measure fPSA (P = 0.024). A total of 15 laboratories used age-specific PSA ranges. In 2006, there were >382,000 tPSA and >48,000 fPSA tests costing an estimated €4,900,000. During 2006–2007 tPSA tests increased by 11%; fPSA tests decreased by 36%.
Conclusions
There is considerable inter-laboratory variation in PSA testing practices. Because of the potential clinical consequences, standardisation should be considered. Testing practice was unaffected by the NCF recommendation.
Similar content being viewed by others
References
Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108
Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18:581–592. doi:10.1093/annonc/mdl498
National Cancer Registry Ireland. www.ncri.ie
Drummond FJ, Sharp L, Carsin A-E, Deady S, Comber H (2007) PSA testing and prostate cancer diagnosis in the Republic of Ireland. BJU Int 100(Suppl):3;23
UK National Screening Committee (1998) First report of the National Screening Committee. London: Department of health, 1998. www.nsc.nhs.uk/pdfs/nsc_firstreport.pdf
The National Cancer Forum a strategy for Cancer Control in Ireland (2006) www.dohc.ie/publications/pdf/en_cancer_control_2006.pdf
Drummond FJ, Sharp L, Carsin AE, Kelleher T, Comber H (2008) Questionnaire order significantly increased response to a postal survey sent to primary care physicians. J Clin Epidemiol 61:177–185. doi:10.1016/j.jclinepi.2007.04.012
Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA et al (1993) Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 270:860–864. doi:10.1001/jama.270.7.860
Association of Clinical Biochemists in Ireland (ACBI) guidelines. http://www.acbi.ie/
Määttänen L, Auvinen A, Stenman UH, Tammela T, Rannikko S, Aro J et al (2001) Three-year results of the Finnish prostate cancer screening trial. J Natl Cancer Inst 93:552–553. doi:10.1093/jnci/93.7.552
Ilic D, O’Connor D, Green S, Wilt T (2006) Screening for prostate cancer. Cochrane Database Syst Rev 3:CD004720
Onur R, Ilhan N, Orhan I, Ilhan N (2003) Increased discrimination between benign prostatic hyperplasia and prostate cancer with equimolar total prostate specific antigen measurement. World J Urol 21(1):43–47
Roddam AW, Price CP, Allen NE, Ward AM (2004) Assessing the clinical impact of prostate-specific antigen assay variability and nonequimolarity: a simulation study based on the population of the United Kingdom. Clin Chem 50(6):1012–1016. doi:10.1373/clinchem.2004.031138
Patel D, White PA, Milford Ward A (2000) A comparison of six commercial assays for total and free prostate specific antigen (PSA): the predictive value of the ratio of free to total PSA. BJU Int 85(6):686–689. doi:10.1046/j.1464-410x.2000.00526.x
Bock JL, Klee GG (2004) How sensitive is a prostate-specific antigen measurement? How sensitive does it need to be? Arch Pathol Lab Med 128:341–343
Mistry K, Cable G (2003) Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma. J Am Board Fam Pract 16:95–101
Zhu H, Roehl KA, Antenor JA, Catalona WJ (2005) Biopsy of men with PSA level of 2.6 to 4.0 ng/mL associated with favorable pathologic features and PSA progression rate: a preliminary analysis. Urology 66:547–551. doi:10.1016/j.urology.2005.03.093
Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A et al (1998) Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279:1542–1547. doi:10.1001/jama.279.19.1542
Catalona WJ, Partin AW, Finlay JA, Chan DW, Rittenhouse HG, Wolfert RL et al (1999) Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model. Urology 54:220–224. doi:10.1016/S0090-4295(99)00185-5
Chun FK, Hutterer GC, Perrotte P, Gallina A, Valiquette L, Benard F et al (2007) Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer. BJU Int 100(1):37–41. doi:10.1111/j.1464-410X.2007.06923.x
All Ireland Cancer Statistics 1998–2000. http://www.ncri.ie/pubs/pubs.shtml
Sokoll LJ, Bruzek DJ, Dua R, Dunn W, Mohr P, Wallerson G et al (2002) Short-term stability of the molecular forms of prostate-specific antigen and effect on percent complexed prostate-specific antigen and percent free prostate-specific antigen. Urology 60((4)(Suppl 1)):24–30. doi:10.1016/S0090-4295(02)01723-5
Cartledge JJ, Thompson D, Verril H, Clarkson P, Eardley I (1999) The stability of free and bound prostate-specific antigen. BJU Int 84(7):810–814. doi:10.1046/j.1464-410x.1999.00311.x
Drummond FJ, Comber H (2007) PSA testing–weighing up the evidence. Forum. Clin Focus 7:15–18
Irish Cancer Society Action Prostate Cancer. http://www.cancer.ie/prostate
McGing PG (1998) A study of PSA requests from general practitioners received by one Dublin hospital. Ir Med J 91:61–62
Gavin A, McCarron P, Middleton RJ, Savage G, Catney D, O’Reilly D et al (2004) Evidence of prostate cancer screening in a UK region. BJU Int 93:730–734. doi:10.1111/j.1464-410X.2003.04716.x
Colditz GA, Emmons KM, Vishwanath K, Kerner JF (2008) Translating science to practice: community and academic perspectives. J Public Health Manag Pract 14:144–149
Kerner JF (2008) Integrating research, practice, and policy: what we see depends on where we stand. J Public Health Manag Pract 14:193–198
Connolly D, Black A, Gavin A, Keane PF, Murray LJ (2008) Baseline prostate-specific antigen level and risk of prostate cancer and prostate-specific mortality: diagnosis is dependent on the intensity of investigation. Cancer Epidemiol Biomarkers Prev 17:271–278. doi:10.1158/1055-9965.EPI-07-0515
Acknowledgments
We would like to take the opportunity to thank Dr. Ned Barrett, for all his help during development of the survey instrument and for his support throughout this project. We would also like to thank Mr. Tadhg Hurley for his help and co-operation. Finally, we would like to thank everyone who took the time to complete these surveys. Funding for this project was provided by the Health Research Board and the National Cancer Screening Service.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Drummond, F.J., Sharp, L. & Comber, H. Major inter-laboratory variations in PSA testing practices: results from national surveys in Ireland in 2006 and 2007. Ir J Med Sci 177, 317–323 (2008). https://doi.org/10.1007/s11845-008-0216-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11845-008-0216-1